{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:15:54Z","timestamp":1789251354726,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.esmoop.2022.100594","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:23:58Z","timestamp":1666916638000},"page":"100594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial"],"prefix":"10.1016","volume":"7","author":[{"given":"M.P.","family":"Saunders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"La Thangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100594_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100594_bib3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100594_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100594_bib5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U","article-title":"Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma","volume":"91","author":"Smyrk","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100594_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients\u00a0with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100594_bib7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100594_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2010.18","article-title":"Mismatch repair deficient colorectal cancer in the era of personalized treatment","volume":"7","author":"Hewish","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100594_bib9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100594_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2022.100594_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100594_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100594_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.31791","article-title":"A\u00a0phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","volume":"125","author":"Eyre","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100594_bib14","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/1878-0261.12953","article-title":"Immune modulation underpins the anti-cancer activity of HDAC inhibitors","volume":"15","author":"Blaszczak","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100594_bib15","author":"Bristol-Myers Squibb"},{"issue":"18","key":"10.1016\/j.esmoop.2022.100594_bib16","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2217\/fon-2020-1278","article-title":"Italian results of the PRECONNECT study: safety and efficacy of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"17","author":"Zaniboni","year":"2021","journal-title":"Future Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:26:44Z","timestamp":1718782004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2059702922002241"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100594","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100594"}}